@article{e7011c371c8a42c39afa718eb39e0ae1,
title = "Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)",
abstract = "The immune responses of 10 patients with advanced non-small cell lung cancer receiving monthly intratumoral injections of a recombinant adenovirus containing human wild-type p53 (Ad-p53) to adenovirus and transgene antigens were studied. The predominate cellular and humoral immune responses as measured by lymphocyte proliferation and neutralizing antibody (Ab) formation were to adenovirus serotype 5 vector antigens, with increased responses in posttreatment samples. Consistent alterations in posttreatment cellular and humoral immune responses to p53 epitopes were not observed, and cytotoxic Abs to human tung cancer cells were not generated. Patients in this study had evidence of an antitumoral effect of this treatment with prolonged tumor stability or regression; however, neither Abs to p53 protein nor increased lymphocyte proliferative responses to wild-type or mutant p53 peptides have been consistently detected.",
keywords = "Adenovirus vector, Anti-p53 antibodies, Lung cancer, Lymphocyte proliferation, p53",
author = "Nancy Yen and Ioannides, {Constantin G.} and Kai Xu and Swisher, {Stephen G.} and Lawrence, {David D.} and Kemp, {Bonnie L.} and El-Naggar, {Adel K.} and Cristiano, {Richard J.} and Bingliang Fang and Glisson, {Bonnie S.} and Hong, {Waun K.} and Khuri, {Fadlo R.} and Kurie, {Jonathan M.} and Lee, {J. Jack} and Lee, {Jin S.} and Merritt, {James A.} and Tapas Mukhopadhyay and Nesbitt, {Jonathan C.} and Dao Nguyen and Roman Perez-Soler and Pisters, {Katherine M.W.} and Putnam, {Joe B.} and Schrump, {David S.} and Shin, {Dong M.} and Walsh, {Garrett L.} and Roth, {Jack A.}",
note = "Funding Information: This study was supported in part by Grant R01 CA45187 from the National Cancer Institute and the National Institutes of Health, by Grant P50-CA70907 from the Specialized Program of Research Excellence in Lung Cancer, by gifts to the Division of Surgery and Anesthesiology from Tenneco and Exxon for the Core Laboratory Facility, by University of Texas MD Anderson Cancer Center Support Core Grant CA16672, and by a sponsored research agreement with Introgen Therapeutics, Inc.",
year = "2000",
doi = "10.1038/sj.cgt.7700138",
language = "English (US)",
volume = "7",
pages = "530--536",
journal = "Cancer gene therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "4",
}
